home / stock / calt / calt news


CALT News and Press, Calliditas Therapeutics AB From 09/14/21

Stock Information

Company Name: Calliditas Therapeutics AB
Stock Symbol: CALT
Market: NASDAQ

Menu

CALT CALT Quote CALT Short CALT News CALT Articles CALT Message Board
Get CALT Alerts

News, Short Squeeze, Breakout and More Instantly...

CALT - PDUFA goal date extension for Nefecon NDA in the U.S.

PDUFA goal date extension for Nefecon NDA in the U.S. PR Newswire STOCKHOLM , Sept. 14, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") (Nasdaq Stockholm: CALTX) (Nasdaq – CALT) , a biopharma company focuse...

CALT - Wall Street Breakfast: The Week Ahead (Podcast)

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

CALT - Catalyst watch for next week: Apple, Zoom Video, Palo Alto Networks in the spotlight; OPEC update

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

CALT - FDA action dates, catalysts, and other events for pharma/biotech in September

With Labor Day marking the unofficial end of summer, September looks to be a busy month for events impacting pharmaceutical and biotechnology  companies. Here's a look at what events to look forward to this month that could impact pharma and biotech stocks. Sept. 3: FDA Cellular, Tissue,...

CALT - Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success

Shares of Travere Therapeutics remain well below this year's highs despite PROTECT study success. The regulatory update on the FSGS indication of sparsentan has weighed on the share price along with the poor biotech sentiment. While there is uncertainty for the FSGS indication, th...

CALT - Calliditas Therapeutics: Interim Report Q2, 2021

Calliditas Therapeutics: Interim Report Q2, 2021 Filing of Marketing Authorisation Application on accelerated basis with EMA PR Newswire STOCKHOLM , Aug. 19, 2021 /PRNewswire/ -- "Following the filing for accelerated approval with the FDA in Q1, we filed our ...

CALT - BHP, Petroleo Brasileiro, Roblox among premarket losers' pack

Qualigen Therapeutics QLGN -29% on Q2 earnings release Sema4 Holdings SMFR -20% on Q2 earnings release Lightning eMotors ZEV -14% on Q2 earnings release Arcimoto FUV -13% on Q2 earnings release Calliditas Therapeutics (NASDAQ:CALT) -13%. Romeo Power RMO...

CALT - ASRT, GOCO, AEYE among mid-day movers

Gainers: NanoVibronix (NASDAQ:NAOV) +47%. Enlivex Therapeutics (NASDAQ:ENLV) +20%. GoHealth (NASDAQ:GOCO) +16%. Travere Therapeutics (NASDAQ:TVTX) +16%. Collegium Pharmaceutical (NASDAQ:COLL) +16%. Auddia (NASDAQ:AUUD) +15%. AudioEye (NASDAQ:AEYE) +14%. Cohen & Company (NYSE:COHN) +14%. F...

CALT - Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 million

Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 million PR Newswire NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STA...

CALT - Calliditas' setanaxib nabs Fast Track tag in U.S. for chronic liver disease

The FDA has granted Fast Track Designation to Calliditas Therapeutics' (NASDAQ:CALT) lead NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Fast Track status provides for more frequent interaction with the ...

Previous 10 Next 10